Preparation method and application of tumour cell specific polyclonal T cells

A tumor cell, specific technology, applied in the fields of molecular biology and cellular immunology, can solve the problems of high cost, time-consuming and laborious, limited application scope, etc., and achieve the effect of reducing production costs.

Inactive Publication Date: 2015-05-20
马飞
View PDF1 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the dual-target specific antibodies used in this technology involve in vitro production, purification, packaging, transportation, storage, etc., so the cost is high and time-consuming; in addition, the polyclonal T cells prepared by this technology only target B cells Department of tumors, the scope of application is very limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and application of tumour cell specific polyclonal T cells
  • Preparation method and application of tumour cell specific polyclonal T cells
  • Preparation method and application of tumour cell specific polyclonal T cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1: This example provides a method for constructing a recombinant lentiviral expression vector capable of stably expressing CD20 on the cell membrane surface and secreting anti-CD20×CD3, including the following steps:

[0051] (1) This example provides a method for constructing a pUC57 recombinant plasmid vector containing CD20×CD3 gene

[0052] (1a) Synthesize the sequentially connected Xba I restriction site-the base sequence encoding the signal peptide of the immunoglobulin κ chain (SEQ ID NO:1)-the base sequence encoding the Flag tag (SEQ ID NO:1) by means of whole gene sequence synthesis NO:2)-BsAb base sequence (SEQ ID NO:3)-base sequence encoding histidine His6 tag (SEQ ID NO:4)-P2A base sequence (SEQ ID NO:5)-NheI enzyme The cleavage site, the sequentially connected base sequences described in this example are only one of the double strands of the gene (that is, the DNA fragment) synthesized by the whole gene, and the other strand is complementary to the ...

Embodiment 2

[0071] Example 2: This example provides a method for constructing HepG2 cells (named: HepG2-BsAb.TAg) that can stably express CD20 on the cell membrane surface and secrete CD20×CD3, including the following steps:

[0072] (1) Recombinant lentiviral particles transfect HepG2

[0073] HepG2 cells were cultured according to conventional methods, and the cell density was adjusted to 5×10 with DMEM / F12 complete medium containing 100 mL / L fetal bovine serum. 5 / mL, trypsinize HepG2 1 day before transfection, and re-inoculate in the culture flask; when the cell growth confluence reaches 70%-80%, replace with a new culture, and add 20 μL of recombinant lentiviral particles. After 4 hours of infection, the culture medium was changed and the culture was continued, and the empty vector without the target gene was used as the control.

[0074] (2) Screening for stable expression strains

[0075] 48 h after infection, puromycin was added at a final concentration of 2 g / L to screen for st...

Embodiment 3

[0083] Example 3: This example provides a method for preparing HepG2-BsAb.TAg-mediated TSPT cells, including the following steps:

[0084] (1) Peripheral venous blood was collected from patients, and mononuclear cells were obtained by density gradient centrifugation of Ficoll-diatrizoate glucosamine. The specific steps are: double-dilute the precipitated blood cells with normal saline, add human lymphocyte separation solution and diluted blood into the centrifuge tube at a ratio of 1:2, centrifuge at 2000 rpm for 20 min, carefully absorb the buffy coat layer, and wash with normal saline Centrifuge twice at 1600 rpm and 1300 rpm for 7 min to obtain PBMC.

[0085] (2) Resuspend the above PBMC in commercial serum-free medium such as PAA? or GT-T551?, and adjust the cell density to 1×10 6 / ml, mixed with HepG2-BsAb.TAg of equal volume and density, added rhIL-2 after mixing, the final concentration was 300 IU / ml, and cultured in an incubator at 37°C and 5% CO2; after 48 hours, Cou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical fields of molecular biology and cellular immunology and in particular relates to a preparation method of tumour cell specific polyclonal T cells. The preparation method of the tumour cell specific polyclonal T cells comprises the following steps: (1) obtaining peripheral blood mononuclear cells; (2) mixing the obtained peripheral blood mononuclear cells with gene modifying tumour cells; and (3) resuspending the obtained mixed cells in a culture medium containing cell factors which can maintain cell growth, proliferation and differentiation. The prepared tumour cell specific polyclonal T cells are mainly applied to medicines which are sued for preventing or treating cancers. The preparation method of the tumour cell specific polyclonal T cells has the advantages that the prepared tumour cell specific polyclonal T cells have the characteristics of large quantity, high specificity and strong killing capability; besides, a technology is simple, and the preparation cost is obviously reduced compared with the prior art.

Description

technical field [0001] The invention relates to the technical fields of molecular biology and cellular immunology, in particular to a method for preparing tumor cell-specific polyclonal T cells, and the application of the tumor cell-specific polyclonal T cells prepared by the method in drugs for preventing or treating cancer . Background technique [0002] At present, adoptive immune cell therapy has made breakthroughs in the treatment of melanoma and hematological tumors; therefore, it has once again become a hot spot in the field of tumor immunotherapy research. Internationally, the selected effector cells mainly include tumor infiltrating lymphocytes (tumor infiltrating lymphocytes, TILs), tumor antigen or viral antigen-specific cytotoxic T cells (cytotoxic T lymphocytes, CTLs) and chimeric antigen receptor modified T cells ( chimeric antigen receptor modified T lymphocyte, CART); in China, the clinical application is mainly the cytokine induced killer cell (CIK) invente...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0783A61K35/17A61P35/00
Inventor 马飞谢芳
Owner 马飞
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products